BEAM – Beam Therapeutics Inc.
BEAM — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
22.94
Margin Of Safety %
Put/Call OI Ratio
0.32
EPS Next Q Diff
-3.37
EPS Last/This Y
-3.5
EPS This/Next Y
-0.08
Price
24.5
Target Price
50.31
Analyst Recom
1.26
Performance Q
-8.76
Upside
-154.1%
Beta
2.21
Ticker: BEAM
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | BEAM | 27.63 | 0.35 | 0.19 | 13804 |
| 2026-03-10 | BEAM | 26.11 | 0.34 | 1.48 | 13811 |
| 2026-03-11 | BEAM | 25.96 | 0.35 | 1.64 | 13900 |
| 2026-03-12 | BEAM | 25.59 | 0.36 | 1.04 | 14123 |
| 2026-03-13 | BEAM | 25.59 | 0.36 | 1.03 | 14123 |
| 2026-03-17 | BEAM | 25.85 | 0.37 | 3.76 | 14696 |
| 2026-03-18 | BEAM | 25.29 | 0.37 | 1.21 | 14666 |
| 2026-03-19 | BEAM | 25.17 | 0.37 | 0.84 | 14744 |
| 2026-03-20 | BEAM | 24.66 | 0.34 | 1.28 | 14482 |
| 2026-03-23 | BEAM | 25.18 | 0.25 | 0.53 | 10224 |
| 2026-03-24 | BEAM | 23.94 | 0.26 | 1.08 | 10561 |
| 2026-03-25 | BEAM | 23.11 | 0.28 | 0.46 | 10773 |
| 2026-03-26 | BEAM | 23.62 | 0.29 | 0.10 | 11474 |
| 2026-03-27 | BEAM | 22.19 | 0.27 | 0.82 | 12525 |
| 2026-03-30 | BEAM | 21.89 | 0.30 | 0.45 | 13459 |
| 2026-03-31 | BEAM | 23.75 | 0.30 | 0.71 | 13528 |
| 2026-04-01 | BEAM | 24.2 | 0.32 | 0.14 | 14148 |
| 2026-04-02 | BEAM | 24.66 | 0.32 | 0.36 | 14493 |
| 2026-04-06 | BEAM | 24.23 | 0.32 | 0.87 | 14521 |
| 2026-04-07 | BEAM | 24.49 | 0.32 | 0.12 | 14539 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | BEAM | 27.61 | 18.7 | - | -4.31 |
| 2026-03-10 | BEAM | 26.10 | 18.7 | - | -4.31 |
| 2026-03-11 | BEAM | 26.08 | 18.7 | - | -4.31 |
| 2026-03-12 | BEAM | 25.61 | 18.7 | - | -4.31 |
| 2026-03-13 | BEAM | 25.17 | 18.7 | - | -4.31 |
| 2026-03-17 | BEAM | 25.83 | 18.7 | - | -4.31 |
| 2026-03-18 | BEAM | 25.31 | 18.7 | - | -4.31 |
| 2026-03-19 | BEAM | 25.17 | 18.7 | - | -4.31 |
| 2026-03-20 | BEAM | 24.63 | 18.7 | - | -4.32 |
| 2026-03-23 | BEAM | 25.20 | 18.7 | - | -4.32 |
| 2026-03-24 | BEAM | 23.94 | 18.7 | - | -4.32 |
| 2026-03-25 | BEAM | 23.12 | 19.8 | - | -4.29 |
| 2026-03-26 | BEAM | 23.62 | 19.8 | - | -4.29 |
| 2026-03-27 | BEAM | 22.21 | 19.8 | - | -4.29 |
| 2026-03-30 | BEAM | 21.90 | 18.9 | - | -4.30 |
| 2026-03-31 | BEAM | 23.84 | 18.4 | - | -4.31 |
| 2026-04-01 | BEAM | 24.20 | 18.4 | - | -4.31 |
| 2026-04-02 | BEAM | 24.66 | 18.4 | - | -4.31 |
| 2026-04-06 | BEAM | 24.22 | 18.4 | - | -4.31 |
| 2026-04-07 | BEAM | 24.50 | 18.4 | - | -4.31 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | BEAM | -1.89 | 3.53 | 21.78 |
| 2026-03-10 | BEAM | -1.89 | 3.53 | 21.78 |
| 2026-03-11 | BEAM | -1.89 | 3.53 | 23.57 |
| 2026-03-12 | BEAM | -1.89 | 3.53 | 23.57 |
| 2026-03-13 | BEAM | -1.89 | 3.53 | 23.57 |
| 2026-03-17 | BEAM | -1.89 | 3.54 | 23.57 |
| 2026-03-18 | BEAM | -1.89 | 3.54 | 23.57 |
| 2026-03-19 | BEAM | -1.89 | 3.54 | 23.57 |
| 2026-03-20 | BEAM | -1.89 | 3.54 | 23.57 |
| 2026-03-23 | BEAM | -1.89 | 3.53 | 23.57 |
| 2026-03-24 | BEAM | -1.89 | 3.53 | 23.57 |
| 2026-03-25 | BEAM | -1.89 | 3.53 | 22.94 |
| 2026-03-26 | BEAM | -1.89 | 3.53 | 22.94 |
| 2026-03-27 | BEAM | -1.89 | 3.53 | 22.94 |
| 2026-03-30 | BEAM | -1.89 | 3.53 | 22.94 |
| 2026-03-31 | BEAM | -1.89 | 3.53 | 22.94 |
| 2026-04-01 | BEAM | -1.89 | 3.53 | 22.94 |
| 2026-04-02 | BEAM | -2.42 | 3.53 | 22.94 |
| 2026-04-06 | BEAM | -1.88 | 3.53 | 22.94 |
| 2026-04-07 | BEAM | -2.50 | 3.53 | 22.94 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.33
Avg. EPS Est. Current Quarter
-1.01
Avg. EPS Est. Next Quarter
-1.04
Insider Transactions
-2.5
Institutional Transactions
3.53
Beta
2.21
Average Sales Estimate Current Quarter
12
Average Sales Estimate Next Quarter
12
Fair Value
Quality Score
27
Growth Score
48
Sentiment Score
87
Actual DrawDown %
82.3
Max Drawdown 5-Year %
-89.1
Target Price
50.31
P/E
Forward P/E
PEG
P/S
17.85
P/B
2.01
P/Free Cash Flow
EPS
-1.02
Average EPS Est. Cur. Y
-4.31
EPS Next Y. (Est.)
-4.39
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-57.24
Relative Volume
0.94
Return on Equity vs Sector %
-33.9
Return on Equity vs Industry %
-17.4
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.09
EBIT Estimation
◆
BEAM
Healthcare
$24.49
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
46.8
Range 1M
46.6%
Sup Dist
2.6%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-440.9%
EPS NY
-3%
52W%
48.1%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+105.4% upside
Upside
+105.4%
Quality
27
Beam Therapeutics Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 511
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
BEAM
Latest News
—
Caricamento notizie per BEAM…
stock quote shares BEAM – Beam Therapeutics Inc. Stock Price stock today
news today BEAM – Beam Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch BEAM – Beam Therapeutics Inc. yahoo finance google finance
stock history BEAM – Beam Therapeutics Inc. invest stock market
stock prices BEAM premarket after hours
ticker BEAM fair value insiders trading